Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening

NANot yet recruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2028

Conditions
Hereditary Cancer Syndromes
Interventions
GENETIC

MyRisk Hereditary Cancer Test

Subjects that are planning to proceed with OCS and enrolled in the trial will be contacted by the genetics clinician (by telephone or in person, based on subject preference) to review the option for HCS in addition to OCS. The WCM genetics clinician will review the potential risks and benefits, possible findings, and implications of findings for HCS. The genetics clinician will follow WCM standards (outlined by the WCM Genetics and Personalized Cancer Prevention Program https://wcinyp.org/GPCP) for informed consent counseling on the potential risks/benefits of HCS. The counseling regarding OCS will have already been performed by the obstetrical team as part of the standard of care. The genetics clinician will review that OCS is being performed as part of the patient's standard of care prenatal visit and HCS is an additional component that is being performed as part of participation in this clinical trial.

Trial Locations (3)

10065

Weill Cornell Medicine, New York

11215

NewYork-Presbyterian Weill Cornell Medicine, Brooklyn

11355

NewYork-Presbyterian Weill Cornell Medicine Queens, Queens

All Listed Sponsors
lead

Weill Medical College of Cornell University

OTHER